See more : Tissue Regenix Group plc (TSSNF) Income Statement Analysis – Financial Results
Complete financial analysis of ProMIS Neurosciences, Inc. (PMN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProMIS Neurosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- H&R Century Union Corporation (000892.SZ) Income Statement Analysis – Financial Results
- Nxu, Inc. (NXU) Income Statement Analysis – Financial Results
- Tintri, Inc. (TNTRQ) Income Statement Analysis – Financial Results
- Anuh Pharma Limited (ANUHPHR.BO) Income Statement Analysis – Financial Results
- Grand Baoxin Auto Group Limited (1293.HK) Income Statement Analysis – Financial Results
ProMIS Neurosciences, Inc. (PMN)
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 8.14K | 1.40K | 920.18 | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
Cost of Revenue | 10.44M | 21.78M | 5.85M | 3.18M | 4.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -10.44M | -21.78M | -5.84M | -3.18M | -4.73M | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
Gross Profit Ratio | 0.00% | 0.00% | -71,796.88% | -227,041.82% | -514,509.20% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 7.88M | 16.09M | 4.95M | 2.50M | 3.63M | 5.44M | 3.15M | 1.39M | 763.96K | 1.27M | 1.77M | 2.04M | 3.25M | 3.62M | 3.27M | 6.06M | 2.95M | 944.20K |
General & Administrative | 7.39M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | -1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 6.38M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 536.21K | 1.20M | 1.17M | 824.00K | 1.22M | 885.47K | 351.62K |
Other Expenses | -5.81M | 115.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
Operating Expenses | 8.45M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
Cost & Expenses | 18.90M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
Interest Income | 0.00 | 0.00 | 4.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 193.63K | 0.00 | 0.00 |
Interest Expense | -201.39K | 282.06K | 415.03K | 0.00 | 0.00 | 0.00 | 5.65K | 15.89K | 23.98K | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 28.04K | 15.19K | 45.83K | 12.33K | 6.55K | 4.90K | 5.31K | 4.96K | 5.50K | 14.78K | 49.45K | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
EBITDA | -17.81M | -29.88M | -9.33M | -4.43M | -5.66M | -7.46M | -4.78M | -2.55M | -1.51M | -2.88M | -2.02M | -2.15M | -2.49M | -3.13M | -4.61M | -3.90M | -6.82M | -3.62M |
EBITDA Ratio | 0.00% | 0.00% | -100,802.23% | -315,985.67% | -614,617.22% | -2,139,026.95% | -60,699.29% | -127,551.65% | -9,929.36% | -1,508.22% | -4,408.57% | -2,730.51% | -261.17% | -2,617.02% | -2,013.48% | -1,470.16% | -1,645.59% | -2,724.12% |
Operating Income | -18.90M | -23.38M | -8.25M | -4.44M | -5.66M | -7.46M | -4.78M | -2.56M | -1.51M | -2.04M | -2.19M | -2.56M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
Operating Income Ratio | 0.00% | 0.00% | -101,363.57% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,766.72% | -127,799.59% | -10,519.49% | -1,519.23% | -4,510.18% | -2,813.90% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,382.95% |
Total Other Income/Expenses | 1.39M | 7.20M | -1.50M | 1.22M | 0.00 | 0.00 | -5.65K | -11.82K | -17.28K | -853.75K | 0.00 | 40.59K | 13.50 | 3.34M | 0.00 | 4.08M | 3.32M | 1.98M |
Income Before Tax | -17.51M | -18.06M | -9.24M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
Income Before Tax Ratio | 0.00% | 0.00% | -113,562.83% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
Income Tax Expense | -167.90K | -5.32M | 415.03K | 0.14 | 0.00 | -156.24K | 5.65K | 11.82K | 17.28K | 0.91 | -2.29K | 2.55M | 3.43M | 4.76M | 4.08M | 6.99M | 3.67M | 1.69M |
Net Income | -17.51M | -12.74M | -9.66M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
Net Income Ratio | 0.00% | 0.00% | -118,662.24% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
EPS | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
EPS Diluted | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
Weighted Avg Shares Out | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
Weighted Avg Shares Out (Dil) | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Source: https://incomestatements.info
Category: Stock Reports